Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice  by Ondondo, Beatrice et al.
A
a
M
B
H
a
b
c
d
a
A
R
R
A
A
K
P
M
P
C
H
C
h
m
p
a
C
r
0
hVaccine 31 (2013) 5594–5601
Contents lists available at ScienceDirect
Vaccine
journa l homepage: www.e lsev ier .com/ locate /vacc ine
bsence of systemic toxicity changes following intramuscular
dministration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and
VA.HIVconsv vaccines to BALB/c mice
eatrice Ondondoa, Caroline Brennanb, Alfredo Nicosiac,d, Steven J. Cromeb, Tomásˇ
ankea,∗
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom
Huntington Life Sciences, Huntington PE28 4HS, United Kingdom
Okairòs, Rome, Italy
CEINGE, Naples, Italy
r t i c l e i n f o
rticle history:
eceived 21 January 2013
eceived in revised form 26 April 2013
ccepted 20 June 2013
vailable online 2 July 2013
eywords:
re-clinical toxicity
odiﬁed vaccinia virus Ankara (MVA)
lasmid DNA
himpanzee adenovirus
IV-1 vaccines
onserved regions of HIV-1
a b s t r a c t
Background: The systemic toxicity of three candidate HIV-1 vaccines plasmid pSG2.HIVconsv DNA (D),
ChAdV63.HIVconsv (C) and MVA.HIVconsv (M) expressing chimeric immunogen derived from the most
conserved regions of the HIV-1 proteome was evaluated in two repeat-dose studies in the male and
female BALB/c mice.
Methods: In study UNO011, mice received three doses of 2×107 plaque-forming units of MVA.HIVconsv
vaccine (MMM). In study UNO012, mice received 3 doses of 50g of pSG2.HIVconsv DNA followed by
a single dose of 5.95×109 virus particles of ChAdV63.HIVconsv vaccine (DDDC). Similarly constituted
control groups received the vehicle alone (phosphate buffered saline) at the same volume-dose. All vac-
cines were administered by intramuscular needle injection into the right hind limb at 14-day intervals
and animals were sacriﬁced 7 days after the last dose. Assessment of local and systemic toxicity was
made. Induction of HIV-1-speciﬁc responses was conﬁrmed. Parameters assessed included clinical con-
dition, body weight, food consumption, ophthalmoscopy, haematology, blood chemistry, organ weight
and macroscopic and microscopic pathology.
Results: In both studies, treatment with the candidate vaccines elicited strong HIV-1-speciﬁc T-cell
responses. Thevaccine treatmentwaswell-toleratedwithout anyadverse systemic toxicological changes.
The local toxicity ﬁndings observed in these studies were consistent with the predicted response to a
vaccine/substance administration by intramuscular injection.
Conclusions: The three novel anti-HIV-1 vaccines were well tolerated when administered by intramuscu-
lar injection to BALB/c mice. These results supported an application for authorisation by the Medicines
and Healthcare Products Regulatory Agency of the UK to test these vaccines for the ﬁrst time in phase
I clinical trials in healthy both uninfected subjects and HIV-1-infected patients stable on antiretroviral
treatment.Abbreviations: MVA, modiﬁed vaccinia virus Ankara; Hct, haematocrit; Hb,
aemoglobin;RBC, erythrocyte;MCHC,meancell haemoglobin concentration;MCV,
ean cell volume; WBC, total white cell count; LUC, large unstained cells; Plt,
latelet; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
minotransferase; gGT, gamma-glutamyl transpeptidase.
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1. Introduction
HIV-1 infection/AIDS continue to be a major health challenge
worldwide, but with more devastating consequences in low-
resource settings such as sub-Saharan Africa and South East Asia,
where the majority of HIV-1-infected people live. A vaccine is
urgently needed, which would on its own or in conjunction with
highly active anti-retroviral treatment prevent new infections,
lower the risk of transmission and/or prevent progression to AIDS.
However, efforts to develop such vaccines are hampered by several
factors including the enormous HIV-1 diversity, and lack of sim-
ple and consistent correlates of immune protection, which would
provide reliable surrogates of vaccine efﬁcacy [1].
reserved.
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Table 1
Summary of animal treatments.
Groupa Treatment Number of animals Dosing
Male Female Day 1 Day 15 Day 29 Day 43
1 Control 10 10 PBS PBS PBS PBS
2 DDDC 10 10 50g
pSG2.HIVconsvb
50g
pSG2.HIVconsv
50g
pSG2.HIVconsv
5.95×109 vp
ChAdV63.HIVconsvb
3 Control 10 10 PBS PBS PBS ND
4 MMM 10 10 2×107 pfu
MVA.HIVconsvc
2×107 pfu
MVA.HIVconsv
2×107 pfu
MVA.HIVconsv
ND
ND – not dosed.
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sa This summarised two studies UNO012 and UNO011 testing toxicity of DDDC an
b Injected volumes i.m. of the pSG2.HIVconsv DNA and ChAdV63.HIVconsv vaccin
c Injected volume i.m. of the MVA.HIVconsv vaccine was 20l.
HIV-1 vaccines derived from conserved regions of the proteome
ould provide an answer to the problem of HIV-1 variability and
scape from immunological control [2]. HIVconsv, a novel T cell
mmunogen designed speciﬁcally to overcome the antigenic vari-
tion of HIV-1, is a chimeric protein assembled from the 14 most
ighly conserved domains among the HIV-1 clade A, B, C and D
roteomes [3]. Several heterologous vaccine modalities and their
ombinations were explored to maximise the induction of HIV-
-speciﬁc T-cell responses [4–8]. Here, three of these vaccines,
amely pSG2.HIVconsv, ChAdV63.HIVconsv and MVA.HIVconsv
ectored by respective plasmid DNA, non-replicating adenovirus
f chimpanzee origin and non-replicating modiﬁed vaccinia virus
nkara,were evaluated inpre-clinical repeat dose studies inBALB/c
ice to assess possible toxic effects associated with intramuscular
dministration prior to their use in humans.
. Materials and methods
.1. Vaccine production and formulation
The pSG2.HIVconsv DNA vaccine [8] was produced by the Clin-
cal Biotechnology Centre (CBC), Bristol Institute for Transfusion
cience, University of Bristol, UK by culture in E. coli strain XL-1
lue. The pSG2.HIVconsv DNA vaccine (Batch no. Pilot 22/05/09)
as formulated in phosphate buffered saline (pH 7.4) at 4.0mg/ml
nd stored frozenat below−70 ◦Cuntil use. TheChAdV63.HIVconsv
accine [8] was produced at the Clinical Biomanufacturing Facil-
ty (CBF) of University of Oxford, UK, by suspension culture in
EK293 cells. The puriﬁed virus was diluted with formulation
uffer to 1.35×1011 virus particles (vp)/ml and stored frozen at
elow −70 ◦C. The MVA.HIVconsv vaccine [8] was produced by
DT Biologika GmbH, Germany, by culture in chick embryo ﬁbro-
lasts (CEF) prepared from Speciﬁc Pathogen Free embryonated
ens’ eggs. MVA.HIVconsv was diluted in a formulation buffer to
.5×108 plaque-forming units (pfu)/ml and stored frozen below
70 ◦C. All cell culture, puriﬁcation and aseptic processing steps in
hemanufacture of these vaccineswere carried out according to the
equirements of cGMP and using the GMP manufacturing process.
.2. Animals
The mouse was chosen as the test species because of its accep-
ance as apredictor of toxic changes inmanand the requirement for
rodent species by regulatory agencies. The BALB/c strainwas used
ecause it allows testing for vaccine potency. A total of 80 BALB/c
ice (40 females and 40 males, 10 animals per study group) aged
–7 weeks obtained from Charles River (UK) Ltd. were used in the
tudy. The mice were within a weight range of 3 g for each sex.M regimens, respectively.
re 50l.
2.3. Vaccine administration
The vaccines were administered as two separate studies. In
UNO0012, three doses of 50g pSG2.HIVconsv (D) were given
at 14-day intervals followed 14 days later by a single dose of
5.95×109 vp of ChAdV63.HIVconsv (C) (regimen DDDC, Group 2).
InUNO0011MVA.HIVconsv (M)was administeredon3occasions at
14-day intervals (regimen MMM, Group 4) at 2×107 pfu per dose.
Mice were killed 7 days after the last dose. Both studies utilised a
control group which received vehicle (phosphate buffered saline
(Groups 1 and 3)) at the same volume dose as the treated group on
the same dosing occasions. Both studies were carried out in accor-
dance with the principles of Good Laboratory Practice (GLP). The
study groups, doses and schedule of administration are summari-
sed in Table 1. All doses were given by intramuscular injection into
the right hind limb.
2.4. Parameters assessed
The following parameters were examined as evaluation for tox-
icity. Mortality and clinical condition – animals were removed from
the cage and observed at least twice daily during the study; on
days of dosing detailed observations were recorded at more fre-
quent intervals. Any deviation from normal in respect of nature
and severity, date and time of onset, duration and progression
was recorded. Local reactions were monitored and recorded by
daily observations of the injection site. Body weight – the weight
of each mouse was recorded one week before treatment com-
menced, on the day that treatment commenced (Day 1), twice
weekly thereafter and before necropsy. Food consumption – the
amount of food supplied to each cage and that leftover includ-
ing estimated spillage was recorded for the week before treatment
and each week throughout the study. Ophthalmoscopy – the eyes of
all animals were examined by means of a binocular indirect oph-
thalmoscope, once before treatment commenced and one day after
the last dose. Prior to each examination, the pupils were dilated
using a tropicamide ophthalmic solution (Mydriacyl). The adnexae,
conjunctiva, cornea, sclera, anterior chamber, iris (pupil dilated),
lens, vitreous and fundus were examined. Haematology (periph-
eral blood) – at termination, animals were held under light general
anaesthesia and blood samples (nominally 0.3ml) were drawn into
tubes containing EDTA anticoagulant and examined for the follow-
ing characteristics using a Bayer Advia 120 haematology analyser:
haematocrit (Hct), haemoglobin concentration (Hb), erythrocyte
count (RBC), reticulocyte count, mean cell haemoglobin (MCH),
mean cell haemoglobin concentration (MCHC), mean cell volume
(MCV), total white cell count (WBC), differential WBC count and
platelet count. Blood chemistry – at termination, further blood
samples (nominally 0.6ml) were collected into lithium heparin
anticoagulant, centrifuge and theplasmaanalysed for the following
blood chemistry parameters: alkaline phosphatase (ALP), alanine
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Table 2
Tissues examined at necropsy, weighed and subjected to histopathological
examination.
Macroscopic abnormalities Parenteral sites (right hind
limb, muscle and overlying
skin)
Adrenals Peyer’s patches
Aorta – thoracic Pituitary
Brain Prostate
Caecum Rectum
Carcass Salivary glands
Colon -Submandibulara,b
Duodenum -Parotida
Epididymides -Sublinguala,b
Eyes Sciatic nervesa
Femursa Seminal vesiclesb
Gall bladder Skeletal musclea
Harderian glands Skin with mammary glands
Heart Spinal cord
Ileum Spleenb
Jejunum Sternum
Kidneysb Stomach
Lachrymal glands Testesb
Larynx Thymusb
Liverb Thyroid with parathyroids
Lungsb Tongue
Lymph nodes Trachea
-Mandibular Ureters
-Popliteal Urinary bladder
Oesophagus Uterus and cervixb
Optic nerves Vagina
Ovariesb
Pancreas
b
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Fig. 1. Induction of T-cell responses by the pSG2.HIVconsvDNA, ChAdV63.HIVconsv
and MVA.HIVconsv vaccines. (A) Groups of 10 male and 10 female mice received 3
doses of 50g of pSG2.HIVconsv DNA followed by a single dose of 5×109 vp of
ChAdV63.HIVconsv at 2-week intervals. A similar (control) group received 4 doses
of PBS. One week after the last dose, the mice were sacriﬁced and the splenocytes
pooled for each group tested for IFN- production by intracellular cytokine stain-
ing. Neg – stimulation with no peptide (negative control); PMA – stimulation with
PMA (positive control); peptide H – stimulation with H peptide present in HIVconsv
immunogen; control males (white), control females (light grey), vaccinated males
(black) andvaccinated females (dark grey). (B)Groupsof 10male and10 femalemice
received 3 doses of 2×107 pfu ofMVA.HIVconsv at 2-week intervals. Oneweek after
the last dose, the mice were sacriﬁced and the splenocytes tested for IFN- produc-
tion by ELISPOT assay. Neg – stimulation with no peptide (negative control); PMAa Only one processed for examination.
b Weighed (salivary glands weighed together, lung weight included mainstem
ronchi).
minotransferase (ALT), aspartate aminotransferase (AST), urea,
reatinine, gamma-glutamyl transpeptidase (gGT), total bilirubin,
lucose, total cholesterol, triglycerides, sodium, potassium, chlo-
ide, calcium, inorganic phosphorus and total protein. Pathology –
full macroscopic and microscopic examination of a wide range of
issueswas performedwith a selection of organsweighed (Table 2).
valuation of vaccine potency and immunogenicity – immunogenic-
ty of the three HIVconsv vaccines was evaluated by testing pooled
plenocytes for HIV-1-speciﬁc CD8+ T-cell responses by inter-
eron (IFN)- ELISPOT assay or intracellular cytokine staining (ICS)
sing peptide H added to the C terminus of the HIVconsv pro-
ein [3]. Antibody responses to the vectors or insert were not
easured.
.5. Statistical analysis
All statistical analyses were carried out separately for males
nd females. Body weight was analysed using gains over appro-
riate study periods. Organ weights were analysed as absolute
nd adjusted for terminal body weight where appropriate. The
ollowing sequence of statistical tests was used for body weight,
rgan weight and clinical pathology data: A parametric analysis
as performed if Bartlett’s test for variance homogeneity was not
igniﬁcant at the 1% level. Groups were compared using t-tests. A
on-parametric analysis was performed if Bartlett’s test was still
igniﬁcant at the 1% level following both logarithmic and square-
oot transformations. Groups were compared using Wilcoxon rank
um tests. For clinical pathology data, if 75% of the data (across all
roups) were the same value, Fisher’s Exact tests were performed.
reatment groups were compared using pairwise comparisons of
ach dose group against the control. For organweight data, analysis
f covariancewas performed using terminal bodyweight as covari-
te. The treatment comparisons were made on adjusted group
eans in order to allow for differences in bodyweight,whichmight– stimulation with PMA (positive control); peptide H – stimulation with H peptide
present in HIVconsv immunogen; vaccinated males (black) and vaccinated females
(dark grey).
inﬂuence the organ weights. Signiﬁcant differences between con-
trol and treated groups were expressed at the 5% (p<0.05) or 1%
(p<0.01) level.
3. Results
3.1. Vaccine take
Both vaccine regimens elicited strong HIV-1-speciﬁc T-cell
responses not detected in unvaccinated controls (Fig. 1).
3.2. Mortality and clinical observations
There were no unscheduled deaths during the course of the
study, and no abnormal or unusual observations of clinical con-
dition considered to be related to vaccine administration.
3.3. Local reactions
Reddening of the skin at the injection site was observed in 4
animals receiving DDDC and in only 1 animal in the control group
(Group 1). In the 4 affected mice, reddening was observed on the
day following pSG2.HIVconsv administration and persisted for up
to 5 days. In 1 of these 4 animals, reddening also occurred follow-
ing ChAdV63.HIVconsv administration. Following MVA.HIVconsv
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Table 3a
Haematology for DDDC.a
Group/sexb Hct (l/l) Hb (g/dl) RBC (×1012/l) Retic (%) MCH (pg) MCHC (g/dl) MCV (ﬂ) WBC (×109/l) N (×109/l) L (×109/l) E (×109/l) B (×109/l) M (×109/l) LUC (×109/l) Plt (×109/l)
1M Mean 0.518 16.0 10.69 2.21 15.0 30.8 48.4 4.48 0.87 3.37 0.12 0.01 0.09 0.03 1100
SD 0.0073 0.25 0.159 0.115 0.15 0.17 0.49 1.667 0.295 1.297 0.041 0.005 0.033 0.026 48.5
2M Meanc 0.512 15.9 10.67 2.28 14.9 31.0 48.1 6.80** 1.20* 5.28** 0.13 0.01* 0.13* 0.05 1198**
SD 0.0097 0.23 0.210 0.144 0.31 0.42 0.80 1.172 0.223 1.108 0.051 0.005 0.042 0.012 65.0
1F Mean 0.492 15.3 9.87 2.26 15.5 31.2 49.8 2.89 0.54 2.21 0.07 0.00 0.05 0.02 1018
SD 0.0090 0.33 0.217 0.344 0.14 0.46 0.83 1.522 0.332 1.181 0.033 0.005 0.021 0.013 23.2
2F Meanc 0.509* 16.0* 10.46** 2.88* 15.3* 31.4 48.7** 4.00 0.85 2.94 0.09 0.01 0.09 0.02 1119**
SD 0.0167 0.64 0.387 0.683 0.17 0.68 0.86 2.407 0.545 1.796 0.053 0.005 0.057 0.021 90.3
Hct – haematocrit; Hb – haemoglobin; RBC – erythrocyte; Retic – reticulocyte; MCHC – mean cell haemoglobin concentration; MCV – mean cell volume; WBC – total white cell count; N – neutrophils; L – lymphocytes; E –
eosinophils; B – basophils; M – monocytes; LUC – large unstained cells; Plt – platelet.
a Animals received 3 doses i.m. of pSG2.HIVcosv DNA followed by 1 dose i.m. of ChAdV63.HIVconsv.
b 1M – males control; 2M – males receiving DDDC; 1F – females control; 2F – females receiving DDDC.
c t-Test: *p<0.05, **p<0.01.
Table 3b
Haematology for MMM.a
Group/sexb Hct (l/l) Hb (g/dl) RBC (×1012/l) Retic (%) MCH (pg) MCHC (g/dl) MCV (ﬂ) WBC (×109/l) N (×109/l) L (×109/l) E (×109/l) B (×109/l) M (×109/l) LUC (×109/l) Plt (×109/l)
1M Mean 0.466 15.8 10.62 2.59 14.8 33.8 43.9 1112 6.90 0.98 5.61 0.10 0.01 0.15 0.05
SD 0.0143 0.43 0.318 0.192 0.21 0.48 0.57 23.9 0.866 0.259 0.683 0.015 0.006 0.048 0.010
2M Meanc 0.458 15.3* 10.58 2.49 14.5** 33.4 43.3* 1053** 4.25** 0.66** 3.28** 0.17** 0.00** 0.10* 0.02**
SD 0.0078 0.40 0.241 0.242 0.14 0.52 0.53 41.0 0.937 0.079 0.849 0.049 0.005 0.044 0.008
1F Mean 0.449 15.3 10.08 2.50 15.2 34.1 44.6 973 3.93 0.73 2.99 0.09 0.00 0.11 0.02
SD 0.0059 0.39 0.218 0.277 0.20 0.59 0.54 49.8 1.246 0.219 1.097 0.034 0.005 0.031 0.011
2F Meanc 0.463* 15.6 10.28 2.30 15.2 33.7 45.0 1047 4.31 0.75 3.33 0.12 0.01* 0.08 0.03
SD 0.0172 0.38 0.322 0.389 0.43 1.09 0.35 90.8 1.476 0.317 1.242 0.031 0.004 0.016 0.019
Hct – haematocrit; Hb – haemoglobin; RBC – erythrocyte; Retic – reticulocyte; MCHC – mean cell haemoglobin concentration; MCV – mean cell volume; WBC – total white cell count; N – neutrophils; L – lymphocytes; E –
eosinophils; B – basophils; M – monocytes; LUC – large unstained cells; Plt – platelet.
a Animals received 3 doses i.m. of MVA.HIVcosv.
b 1M – males control; 2M – males receiving MMM; 1F – females control; 2F – females receiving MMM.
c t-Test: *p<0.05, **p<0.01.
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administration, swelling of the injection sitewas observed in only 1
male on day 2 and this persisted until day 6. There was no swelling
noted for the rest of the animals of Groups 3 and 4. These local
effects resolved fully in all animals and were considered to be
related to the administration procedure rather than the vaccines.
3.4. Body weight
Minor changes in body weight were recorded particularly in
females, but there were no statistical differences between con-
trols and treated animals. Fluctuations in body weight do occur
and overall, the changes observed in these studies reﬂected normal
variability rather than speciﬁc association with the vaccines.
3.5. Food consumption
There were no apparent differences in mean food consump-
tion between the control and treatment groups, hence no effect
of vaccine administration on food consumption.
3.6. Ophthalmoscopy
There were no ophthalmic ﬁndings observed following treat-
ment with any vaccine that differed from those observed
pretreatment or in the control mice. Thus, there was no effect of
treatment.
3.7. Haematology
For the DDDC regimen, signiﬁcantly higher haematocrit,
haemoglobin and RBC counts were observed in treated females,
but not treated males when compared to controls (Table 3a).
These parameters were above the concurrent control range in
majority of treated animals and were associated with signiﬁcantly
higher MCH and MCV. Similarly, reticulocyte count was signif-
icantly higher in treated females compared to female controls.
Neutrophil, lymphocyte, basophil and monocyte counts were sta-
tistically signiﬁcantly elevated only in treated males. Additionally,
a slight, but statistically signiﬁcant elevation in platelet count was
observed amongst treatedmales and femaleswhen comparedwith
controls. For mainly males receiving MMM, there were statistically
signiﬁcant lower cell counts compared to controls in several of
the parameters tested (Table 3b) but these were associated with
some unusually high control values and were considered unrelated
to vaccine administration. The rest of examined parameters and
histopathological analysis found no evidence of vaccine-associated
toxicological effects.
3.8. Blood chemistry
Analysis of biochemical parameters in both females and males
receiving MMM (Table 3c) showed signiﬁcantly higher ALT and
AST levels compared to controls. For example, the mean ALT
levels amongst the males were 56 and 40U/l for treated and con-
trols, respectively (p<0.01), while the AST levels were 91 and 54,
respectively (p<0.01). The-globulin concentrationswere also sig-
niﬁcantly increased in both treated sexes compared to controls,
and this was reﬂected in the slightly higher total protein values
and a marginal, but signiﬁcantly lower A/G ratio. The rest of the
parameters had no signiﬁcant vaccine effects.
In the DDDC treatment group (Table 3c), there was a trend for
higher glucose concentration in females and a higher plasma con-
centration of potassium in treated males and females compared
to controls. The differences amongst the males reached statisti-
cal signiﬁcance. In treated versus untreated females, there was a
signiﬁcantly lower concentration of urea, but this was considered
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Table 4
Tissue enlargement.
Group Treatment Day of
examination
Number of animals/
tissues examined
Organ/tissue examineda
Spleen Popliteal lymph node
(right)
Inguinal lymph node
(right)
Male Female Male Female Male Female
1 Control Day 50 10 0 0 0 0 0 0
2 DDDCb Day 50 10 0 5/10 0 0 0 0
3 Control Day 36 10 0 0 0 0 0 0
4 MMMc Day 36 10 0 0 9/10 8/10 6/10 8/10
a The numbers in the table indicate the number of animals in each group with signiﬁcantly enlarged organs.
b Animals received 3 doses i.m. of pSG2.HIVcosv DNA followed by 1 dose i.m. of ChAdV63.HIVconsv.
c Animals received 3 doses i.m. of MVA.HIVconsv.
Table 5
Microscopic pathology at the injection site.a
Observation Group 1 (control) Group 2 (DDDCb) Group 3 (control) Group 4 (MMMc)
Male Female Male Female Male Female Male Female
Myoﬁbre inﬂammation 0 0 10/10 9/10 – – – –
Myoﬁbre regeneration 0 0 5/10 8/10 – – – –
Myoﬁbre necrosis/degeneration 0 0 3/10 3/10 – – – –
Interstitial inﬂammation 0 0 4/10 9/10 – – – –
Intermyoﬁbre/interfascicular/perimysial
inﬂammatory cell inﬁltrate
– – – – 0 0 10/10 10/10
–
10
c
t
c
g
g
m
a
t
3
a
a
w
i
w
m
p
t
b
c
T
MDermal inﬂammatory cell inﬁltrate – –
Number of tissues examined 10 10
oincidental due to overall variability. Finally, triglyceride concen-
ration for DDDC-treated males was signiﬁcantly higher than in
ontrolswhile in females triglyceride concentrationwas lower sug-
esting somewhat random variations.
Overall, the differences between the vaccinated and control
roups including those attaining statistical signiﬁcance were only
odest and considered to be within the range expected for the
ge and strain of animals and were, therefore, not attributed to the
reatment.
.9. Organ weights, macropathology and histopathology
Organ weights were adjusted for body weight as a covari-
te as part of the analysis. Thus, the spleens from both DDDC-
nd MMM-treated males and females had signiﬁcantly higher
eights than controls (Table 4). Histopathological examination
ndicated extramedullary haemopoiesis in the spleens consistent
ith immune stimulation. Unlike animals treated with DDDC,
ajority of females and males receiving MMM had enlarged
opliteal and inguinal lymph nodes (Table 4). Amongst the MMM-
reated bothmales and females, liverweightswere alsomarginally,
ut signiﬁcantly increased, however, there was no histopathology
orrelation to indicate any toxicological importance. The incidence
able 6
icroscopic changes in the lymph nodes.a
Observation Group1 (control)Group2 (DDDCb)Group3 (co
Popliteal Inguinal Popliteal
M F M F M F
Increased cellularity – generalised 0 1/10 0 0 7/10 6
Plasmacytosis 0 0 0 0 4/10 1
Perinodal Inﬂammation 0 0 0 0 5/10 1
Increased germinal centre development – – – – – –
Number of tissues examined 8 10 10 10 10 9
a The numbers in the table indicate the number of animals in each group with signiﬁca
b Animals received 3 doses i.m. of pSG2-HIVcosv DNA followed by 1 dose i.m. of ChAdV
c Animals received 3 doses i.m. of MVA.HIVconsv.– 4/10 5/10 6/10 8/10
10 10 10 10 10
and distribution of all other organweightswaswithin the expected
normal range.
Microscopic examination of tissues from Groups 1 and 2
revealed histopathological changes related to DDDC vaccine
administration, which was absent in control animals, only at the
siteof injection (Table5), in the spleenand the rightpopliteal lymph
node (Table 6). Thus, there was detectable interstitial and myoﬁbre
inﬂammation, necrosis as well as regeneration observed at the site
of injection in both males and females treated with DDDC. Treat-
mentwithMMMwasassociatedwith intermyoﬁbre, interfascicular
and perimysial inﬂammatory cell inﬁltrate, which was observed in
all treated animals. Dermal inﬂammatory cell inﬁltrate was also
seen in majority of treated animals, but was also observed amongst
the controls. Among animals treated with DDDC, increased cellu-
larity was observed in the popliteal lymph nodes of both females
and males, while plasmacytosis and perinodal inﬂammation were
more common in males. Plasmacytosis was seen in the inguinal
lymph node of one of the treated females, while another treated
female showedgeneralised increased cellularity in the right lumbar
lymph node. These lymph nodes were only examined at the micro-
scopic level due to abnormality at macroscopic examination and
because similar ﬁndings were not present in the controls or other
DDDC-treatedanimals their signiﬁcance remainsunclear, however,
ntrol)Group 4 (MMMc)
Inguinal Popliteal Inguinal Popliteal Inguinal
M F M F M F M F M F
/9 0 0 – – – – – – – –
/9 0 1/10 0 0 – – 4/10 4/10 – –
/9 0 0 – – – – – – – –
– – 0 0 – – 9/10 10/10 5/6 7/8
10 10 9 9 0 0 10 10 6 8
nt microscopic changes.
63.HIVconsv.
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by electroporated alphavirus replicon DNA compared to conventional plasmid
DNA vaccine. J Virol 2012;86(February):4082–90.
[6] Letourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, Yang H, et al. Design600 B. Ondondo et al. / Va
n immune response cannot be ruled out. Increased germinal cen-
re development was found mainly in the popliteal lymph nodes
nd to a lesser extent the inguinal lymph nodes of both male and
emale animals receivingMMM. Plasmacytosiswas only seen in the
opliteal lymph nodes. No other changes in the tissues presented
or histopathological evaluation were considered to be related to
revious treatment with the vaccines.
. Discussion and conclusions
Here, we report on two GLP pre-clinical studies UNO011
nd UNO012 evaluating the systemic toxicity of three candi-
ate HIV-1 vaccines pSG2.HIVconsv DNA, ChAdV63.HIVconsv and
VA.HIVconsv administered intramuscularly, either singly or in
ombination, to adult male and female BALB/c mice.
In UNO011, following 3 doses of MVA.HIVconsv, no unsched-
led deaths were recorded and treatment was well-tolerated and
ot associated with any systemic toxicological changes. The only
reatment-related effects seen were those attributable to inﬂam-
atory and immune responses mainly at the injection site and in
he draining immune organs, consistent with a predicted response
o intramuscular vaccine administration. These changes included
ncreased cellularity of the draining lymph nodes, high plasma
-globulin concentration, elevated ALT/AST levels and inﬂamma-
ion. The MVA.HIVconsv vaccine was therefore concluded to be
afe and well-tolerated in the chosen model. Based on mouse
nd human body weights of 25g and 65kg, respectively, a dose
evel of 2×107 pfu given to the mouse corresponds to a dose of
.2×1010 pfu in humans, i.e. represents a 260-fold safety margin
ver the clinical dose of 2×108 pfu. The results of UNO011 sup-
orted authorisation of phase I trial HIV-CORE 001 of the MMM
egimen delivering low and high doses i.m. of 5×107 pfu and
×108 pfu, respectively, to HIV-1-positive individuals stable on
ighly active anti-retroviral treatment (EudraCT no. 2009-012662-
1).
In UNO012, 3 doses of the pSG2.HIVconsv DNA followed by
dose of the ChAdV63.HIVconsv vaccines administered intra-
uscularly were also well-tolerated and not associated with any
dverse systemic toxicological changes. Treatment-related effects
bserved were those attributable to inﬂammatory and immune
esponses at the injection site, in the draining lymph node and the
pleen. Neutrophil, lymphocyte and monocyte counts were ele-
ated in both male and female DDDC-treated animals, possibly
ue to an immune response to the vaccines, or secondary to the
nﬂammatory response at the site of administration. Other ﬁnd-
ngs includedmarginally higher red cell indices and plasma glucose
n treated females, and higher platelet counts and potassium in
oth sexes and were also attributable to the vaccine combination,
ut were not considered to be adverse at the degree observed.
owever, a single treated female showed plasmacytosis of the
ight inguinal lymph node and generalised increased cellularity
f the right lumbar lymph node, which were unexplained. As in
NO011, all toxicity ﬁndings in the study were consistent with the
redicted response to intramuscular vaccine administration. Thus
he pSG2.HIVconsv DNA and ChAdV63.HIVconsv vaccines were
oncluded to be safe and well-tolerated when given to BALB/c
ice at dose levels of 50g and 5×109 vp, respectively. Based
n mouse and human body weights, a dose level of 50g DNA
n the mouse corresponds to a dose level of 130mg in humans.
he dose level of the pSG2.HIVconsv vaccine used in the mouse
tudy therefore represents a 32.5-fold safety margin over the pro-
osed clinical dose of 4mg DNA. On the same basis, a dose level
f 5.95×109 vp of ChAdV63.HIVconsv in the mouse corresponds
o a dose level of 1.6×1013 vp in humans and therefore represents
n approximately 3000-fold safety margin over the lower clinical1 (2013) 5594–5601
dose of 5×109 vp and an approximately 300-fold safety margin
over the higher clinical dose of 5×1010 vp. The results of UNO012
and UNO011 supported authorisation of phase I trial HIV-CORE
002 in healthy, HIV-1/2-negative subjects in Oxford, UK. The trial
startedwith a low i.m. dose of 5×109 vp of ChAdV63.HIVconsv, fol-
lowedby threegroups receivingCM,DDDCMandDDDMCregimens
using i.m. vaccine doses of 4mg pSG2.HIVconsv DNA, 5×1010 vp of
ChAdV63.HIVconsv and 2×108 pfu of MVA.HIVconsv (EudraCT no.
2009-012662-31).
To support the two phase I trials above, certain tests or toxicity
study features were not requested by the regulator at this stage of
the vaccine platform development. These include the N+1 study
design, the highest doses given to humans were not given to mice,
biodistribution and/or potential persistence were not tested, and
coagulation parameters were not monitored. The blood volumes
necessary to assess haematology, blood chemistry and clotting
function cannot be abstracted from a single mouse, so unless there
is an expectation of effect on clotting function, which there was not
in the case of our vaccines, this is commonly excluded from regula-
torymouse toxicity studies. Also biomarkers of acute inﬂammation
are typically investigated in supplementary studies designed to
address speciﬁc ﬁndings from the initial routine studies.
Over the last decade or so for investigators from the Univer-
sity of Oxford alone, 5, 15 and 7 similar GLP toxicity studies were
carriedout forDNA, recombinantMVAandChAdVvaccines, respec-
tively, whereby the vaccines were used alone or in combination
([9] and unpublished). Design of each study was discussed and
agreed with MHRA prior to its commencement. Together, these
toxicity studies supported over 96 clinical trials of over 25 exper-
imental subunit vaccine candidates for malaria, TB, HIV, RSV, ﬂu
and cancer. For all these studies, the BALB/c mouse was chosen as
the test species because of its acceptance as a predictor of toxic
changes in man and was used alone. Larger animal studies were
considered, but deemed not necessary. One rhesus macaque GLP
study not requested by MHRA was completed [10]. Thus, for DNA-,
ChAdV- andMVA-vectored vaccines, a growing body of pre-clinical
and clinical data is now accumulating [9–15] facilitating safe, but
rapid translation of iterative improvements in immunogen and/or
regimen designs from bench to clinic.
Acknowledgements
The work was supported by Medical Research Council UK.
The authors would like to thank the team at Huntington Life
Sciences, UK for their advice and excellent technical expertise.
References
[1] Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM,
et al. Immune-correlates analysis of an HIV-1 vaccine efﬁcacy trial. N Engl J
Med 2012;366(April (14)):1275–86.
[2] Hanke T, McMichael AJ. HIV-1: from iscapism to conservatism. Eur J Immunol
2011;41:3390–3.
[3] Letourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, et al.
Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE
2007;2(10):e984.
[4] Im E-J, Hong JP, Roshorm Y, Bridgeman A, Létourneau S, Liljeström P, et al. Pro-
tective efﬁcacy of serially up-ranked subdominant CD8+ T cell epitopes against
virus challenges. PLoS Pathog 2011;7:e1002041.
[5] KnudsenML,Mbewe-MvulaA, RosarioM, JohanssonDX, KakoulidouM, Bridge-
man A, et al. Superior induction of T cell responses to conserved HIV-1 regionsandpre-clinical evaluationof auniversalHIV-1vaccine. PLoSONE2007;2:e984.
[7] Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mwula A, Bridgeman A,
Colloca S, et al. Prime-boost regimens with adjuvanted synthetic long peptides
elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS
2012;26:275–84.
ccine 3
[
[
[
[
[B. Ondondo et al. / Va
[8] Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, et al.
Long peptides induce polyfunctional T cells against conserved regions of HIV-
1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol
2010;40(May):1973–84.
[9] Hanke T, McMichael AJ, Samuel RS, Powell LAJ, McLoughlin L, Crome SJ, et al.
Lack of toxicity and persistence in the mouse associated with administration of
candidate DNA- and modiﬁed vaccinia virus Ankara (MVA)-based HIV vaccines
for Kenya. Vaccine 2002;21:109–15.
10] Hanke T, McMichael AJ, Dennise MJ, Sharpe SA, Powell LAJ, Loughlin l Mc, et al.
Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in
SIV-infected rhesus macaques and SCID mice. Vaccine 2005;23:1507–14.
11] Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel
adenovirus-based vaccines induce broad and sustained T cell responses to HCV
in man. Sci Transl Med 2012;4(January (115)):ra1.
[1 (2013) 5594–5601 5601
12] Hanke T, GoonetillekeN,McMichael AJ, Dorrell L. Clinical experiencewith plas-
mid DNA- and modiﬁed vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade
A vaccine inducing T cells. J Gen Virol 2007;88:1–12.
13] O’Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, et al. Clinical
assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine
vector. J Infect Dis 2012;205(March (5)):772–81.
14] Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O’Hara GA, et al. Phase Ia
clinical evaluation of the safety and immunogenicity of the Plasmodium fal-
ciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS
ONE 2012;7(2):e31208.
15] Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, et al. Phase Ia
clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1
in ChAd63 and MVA vaccine vectors. Mol Ther 2012;19(December (12)):
2269–76.
